MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock
Rhea-AI Summary
MAIA Biotechnology (NYSE American: MAIA) closed an underwritten public offering of 20,000,000 shares at $1.50 per share, generating aggregate gross proceeds of $30 million on March 4, 2026. The company granted a 30-day option for up to 3,000,000 additional shares to cover over-allotments.
Proceeds are intended to fund clinical trials and for working capital and general corporate purposes; the offering was led by healthcare-dedicated investors and existing shareholders and was sold under the company’s effective Form S-3 shelf registration.
Positive
- $30 million gross proceeds from common stock offering
- Proceeds earmarked for clinical trials and working capital
- Led by healthcare-dedicated investors and existing shareholders
- Underwritten offering with 30-day 3,000,000-share option
Negative
- Issuance of 20,000,000 shares creates immediate shareholder dilution
- Potential additional dilution from up to 3,000,000 overallotment shares
- Offering priced at $1.50 may reflect constrained near-term financing conditions
Key Figures
Market Reality Check
Peers on Argus
MAIA fell 27.05% while biotech peers were mixed (e.g., CUE up 2.28%, PDSB down 3.72%, ARTV down 1.97%, QNTM up 4.17%), pointing to stock-specific dilution impact.
Previous Offering Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 02 | Equity offering pricing | Negative | -27.1% | Priced 20,000,000-share underwritten offering at $1.50 for $30M gross proceeds. |
| Mar 02 | Offering commencement | Negative | -27.1% | Announced proposed underwritten offering of common stock and pre-funded warrants. |
Recent equity offering headlines have coincided with sharply negative price moves for MAIA.
Over the last few months, MAIA combined financing with clinical progress. On Dec 24, 2025, board members participated in a private placement, increasing insider ownership. In early 2026, updates on ateganosine, including a Phase 3 program and Fast Track status, saw strong positive reactions of up to 26.44%. By Mar 2, 2026, the company shifted focus to an underwritten equity offering, with proposed and then priced deals for 20,000,000 shares at $1.50, which aligned with a -27.05% reaction as investors digested dilution.
Historical Comparison
In prior offering-related headlines, MAIA saw an average move of -27.05%. Today’s closing announcement fits into the same financing sequence, echoing the earlier dilution-driven pressure.
The company progressed from announcing a proposed underwritten offering to pricing 20,000,000 shares at $1.50, and now to closing the deal, all within the same capital-raising track.
Market Pulse Summary
This announcement confirms the closing of MAIA’s underwritten public offering of 20,000,000 shares at $1.50, for gross proceeds of $30 million and additional 30-day over-allotment capacity. Regulatory filings indicate estimated net proceeds of $28.0 million, or $32.3 million with full overallotment. Historically, the company paired financings with clinical updates on its ateganosine program, so investors may monitor how these funds support Phase 3 development and related milestones.
Key Terms
underwritten public offering financial
over-allotments financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. Not financial advice.
Financing included participation by healthcare-dedicated investors alongside
existing shareholders
CHICAGO, IL, March 04, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the closing of its previously announced underwritten public offering of 20,000,000 shares of its common stock at a public offering price of
The offering was structured as a straightforward common stock only investment with no warrant coverage and was led by healthcare-dedicated investors alongside existing shareholders.
Konik Capital Partners, LLC, a division of T.R. Winston & Company acted as the sole book-running manager for the offering.
MAIA intends to use the net proceeds from the offering to conduct clinical trials and for working capital and general corporate purposes.
The securities described above were offered and sold pursuant to a “shelf” registration statement on Form S-3 (File No. 333-273984), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 15, 2023, and declared effective on August 23, 2023.
The offering was made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A prospectus supplement describing the terms of the public offering has been filed with the SEC and forms a part of the effective registration statement.
Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained, on the SEC’s website at http://www.sec.gov or by contacting Konik Capital Partners LLC, a division of T.R. Winston & Company, at 7 World Trade Center, 46th Floor, New York, NY 10007, Attention: Capital Markets Team, Email: capmarkets@konikcapitalpartners.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About MAIA Biotechnology
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
Cautionary Note Regarding Forward-Looking Statements
MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended). Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, and (viii) the use of proceeds of our underwritten public offering of common stock, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. A detailed discussion of these uncertainties and risks that affect our business is contained in our SEC filings, including our reports on Form 10-K and Form 10-Q, particularly under the heading “Risk Factors.” Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com
FAQ
How many shares did MAIA (NYSE:MAIA) sell in the March 4, 2026 offering?
What will MAIA (NYSE:MAIA) use the $30 million raised on March 4, 2026 for?
Who led MAIA’s March 4, 2026 public offering and who participated?
Does MAIA (NYSE:MAIA) have an option to sell more shares after the March 4, 2026 closing?
Were there warrants or other sweeteners included in MAIA’s March 4, 2026 offering?
